Comprehensive analyses identify RIPOR2 as a genomic instability-associated immune prognostic biomarker in cervical cancer

Cervical cancer (CC) is a malignancy that tends to have a poor prognosis when detected at an advanced stage; however, there are few studies on the early detection of CC at the genetic level. The tumor microenvironment (TME) and genomic instability (GI) greatly affect the survival of tumor patients v...

Full description

Bibliographic Details
Main Authors: Fangfang Xu, Chang Zou, Yueqing Gao, Jiacheng Shen, Tingwei Liu, Qizhi He, Shuangdi Li, Shaohua Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.930488/full
_version_ 1828255287367172096
author Fangfang Xu
Chang Zou
Yueqing Gao
Jiacheng Shen
Tingwei Liu
Qizhi He
Shuangdi Li
Shaohua Xu
author_facet Fangfang Xu
Chang Zou
Yueqing Gao
Jiacheng Shen
Tingwei Liu
Qizhi He
Shuangdi Li
Shaohua Xu
author_sort Fangfang Xu
collection DOAJ
description Cervical cancer (CC) is a malignancy that tends to have a poor prognosis when detected at an advanced stage; however, there are few studies on the early detection of CC at the genetic level. The tumor microenvironment (TME) and genomic instability (GI) greatly affect the survival of tumor patients via effects on carcinogenesis, tumor growth, and resistance. It is necessary to identify biomarkers simultaneously correlated with components of the TME and with GI, as these could predict the survival of patients and the efficacy of immunotherapy. In this study, we extracted somatic mutational data and transcriptome information of CC cases from The Cancer Genome Atlas, and the GSE44001 dataset from the Gene Expression Omnibus database was downloaded for external verification. Stromal components differed most between genomic unstable and genomic stable groups. Differentially expressed genes were screened out on the basis of GI and StromalScore, using somatic mutation information and ESTIMATE methods. We obtained the intersection of GI- and StromalScore-related genes and used them to establish a four-gene signature comprising RIPOR2, CCL22, PAMR1, and FBN1 for prognostic prediction. We described immunogenomic characteristics using this risk model, with methods including CIBERSORT, gene set enrichment analysis (GSEA), and single-sample GSEA. We further explored the protective factor RIPOR2, which has a close relationship with ImmuneScore. A series of in vitro experiments, including immunohistochemistry, immunofluorescence, quantitative reverse transcription PCR, transwell assay, CCK8 assay, EdU assay, cell cycle detection, colony formation assay, and Western blotting were performed to validate RIPOR2 as an anti-tumor signature. Combined with integrative bioinformatic analyses, these experiments showed a strong relationship between RIPOR2 with tumor mutation burden, expression of genes related to DNA damage response (especially PARP1), TME-related scores, activation of immune checkpoint activation, and efficacy of immunotherapy. To summarize, RIPOR2 was successfully identified through comprehensive analyses of the TME and GI as a potential biomarker for forecasting the prognosis and immunotherapy response, which could guide clinical strategies for the treatment of CC patients.
first_indexed 2024-04-13T02:11:59Z
format Article
id doaj.art-ca87e04aaee2411084aebe695a517c43
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-04-13T02:11:59Z
publishDate 2022-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-ca87e04aaee2411084aebe695a517c432022-12-22T03:07:16ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-08-011310.3389/fimmu.2022.930488930488Comprehensive analyses identify RIPOR2 as a genomic instability-associated immune prognostic biomarker in cervical cancerFangfang Xu0Chang Zou1Yueqing Gao2Jiacheng Shen3Tingwei Liu4Qizhi He5Shuangdi Li6Shaohua Xu7Department of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Pathology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, ChinaCervical cancer (CC) is a malignancy that tends to have a poor prognosis when detected at an advanced stage; however, there are few studies on the early detection of CC at the genetic level. The tumor microenvironment (TME) and genomic instability (GI) greatly affect the survival of tumor patients via effects on carcinogenesis, tumor growth, and resistance. It is necessary to identify biomarkers simultaneously correlated with components of the TME and with GI, as these could predict the survival of patients and the efficacy of immunotherapy. In this study, we extracted somatic mutational data and transcriptome information of CC cases from The Cancer Genome Atlas, and the GSE44001 dataset from the Gene Expression Omnibus database was downloaded for external verification. Stromal components differed most between genomic unstable and genomic stable groups. Differentially expressed genes were screened out on the basis of GI and StromalScore, using somatic mutation information and ESTIMATE methods. We obtained the intersection of GI- and StromalScore-related genes and used them to establish a four-gene signature comprising RIPOR2, CCL22, PAMR1, and FBN1 for prognostic prediction. We described immunogenomic characteristics using this risk model, with methods including CIBERSORT, gene set enrichment analysis (GSEA), and single-sample GSEA. We further explored the protective factor RIPOR2, which has a close relationship with ImmuneScore. A series of in vitro experiments, including immunohistochemistry, immunofluorescence, quantitative reverse transcription PCR, transwell assay, CCK8 assay, EdU assay, cell cycle detection, colony formation assay, and Western blotting were performed to validate RIPOR2 as an anti-tumor signature. Combined with integrative bioinformatic analyses, these experiments showed a strong relationship between RIPOR2 with tumor mutation burden, expression of genes related to DNA damage response (especially PARP1), TME-related scores, activation of immune checkpoint activation, and efficacy of immunotherapy. To summarize, RIPOR2 was successfully identified through comprehensive analyses of the TME and GI as a potential biomarker for forecasting the prognosis and immunotherapy response, which could guide clinical strategies for the treatment of CC patients.https://www.frontiersin.org/articles/10.3389/fimmu.2022.930488/fullRIPOR2cervical cancergenomic instabilitytumor microenvironmentprognostic model
spellingShingle Fangfang Xu
Chang Zou
Yueqing Gao
Jiacheng Shen
Tingwei Liu
Qizhi He
Shuangdi Li
Shaohua Xu
Comprehensive analyses identify RIPOR2 as a genomic instability-associated immune prognostic biomarker in cervical cancer
Frontiers in Immunology
RIPOR2
cervical cancer
genomic instability
tumor microenvironment
prognostic model
title Comprehensive analyses identify RIPOR2 as a genomic instability-associated immune prognostic biomarker in cervical cancer
title_full Comprehensive analyses identify RIPOR2 as a genomic instability-associated immune prognostic biomarker in cervical cancer
title_fullStr Comprehensive analyses identify RIPOR2 as a genomic instability-associated immune prognostic biomarker in cervical cancer
title_full_unstemmed Comprehensive analyses identify RIPOR2 as a genomic instability-associated immune prognostic biomarker in cervical cancer
title_short Comprehensive analyses identify RIPOR2 as a genomic instability-associated immune prognostic biomarker in cervical cancer
title_sort comprehensive analyses identify ripor2 as a genomic instability associated immune prognostic biomarker in cervical cancer
topic RIPOR2
cervical cancer
genomic instability
tumor microenvironment
prognostic model
url https://www.frontiersin.org/articles/10.3389/fimmu.2022.930488/full
work_keys_str_mv AT fangfangxu comprehensiveanalysesidentifyripor2asagenomicinstabilityassociatedimmuneprognosticbiomarkerincervicalcancer
AT changzou comprehensiveanalysesidentifyripor2asagenomicinstabilityassociatedimmuneprognosticbiomarkerincervicalcancer
AT yueqinggao comprehensiveanalysesidentifyripor2asagenomicinstabilityassociatedimmuneprognosticbiomarkerincervicalcancer
AT jiachengshen comprehensiveanalysesidentifyripor2asagenomicinstabilityassociatedimmuneprognosticbiomarkerincervicalcancer
AT tingweiliu comprehensiveanalysesidentifyripor2asagenomicinstabilityassociatedimmuneprognosticbiomarkerincervicalcancer
AT qizhihe comprehensiveanalysesidentifyripor2asagenomicinstabilityassociatedimmuneprognosticbiomarkerincervicalcancer
AT shuangdili comprehensiveanalysesidentifyripor2asagenomicinstabilityassociatedimmuneprognosticbiomarkerincervicalcancer
AT shaohuaxu comprehensiveanalysesidentifyripor2asagenomicinstabilityassociatedimmuneprognosticbiomarkerincervicalcancer